

PSAP 2020 Book 2 (*Pulmonary and Gastroenterology*)

Release date: May 15, 2020

BCPS test deadline: 11:59 p.m. (Central) on November 16, 2020.

ACPE test deadline: 11:59 p.m. (Central) on May 15, 2023.



Continuing Pharmacy Education (CPE) Credit: The American College of Clinical

Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of CPE.

PSAP Target Audience: The target audience for PSAP 2020 Book 2 (*Pulmonary and Gastroenterology*) is pharmacotherapy specialists and advanced-level clinical pharmacists encountering patients with pulmonary and gastroenterological disorders.

Module I (5.0 CPE): 0217-0000-20-020-H01-P

Chapter: Asthma

Learning Objectives

1. Assess current evidence regarding therapies specific to the guidelines.
2. Design patient-centered therapy for patients with difficult-to-treat and severe asthma.
3. Design patient-centered therapy for patients with exercise-induced asthma.
4. Evaluate the role and place in therapy of pharmacotherapy on the basis of patient factors.

Chapter: Chronic Obstructive Pulmonary Disease

Learning Objectives

1. Develop interventions on the basis of risk factors, patient status, and chronic obstructive pulmonary disease (COPD) progression.
2. Design initial or maintenance therapy plans on the basis of current clinical evidence and understanding of COPD.
3. Develop non-pharmacotherapy and health maintenance care plans for patients with COPD.
4. Design acute management plans for COPD exacerbations.

Module II (5.5 CPE): 0217-0000-20-021-H01-P

Chapter: Pneumonia

Learning Objectives

1. Apply rapid diagnostic and biomarker testing to the diagnosis of pneumonia.
2. Distinguish HAP/VAP from CAP in presentation and design an appropriate empiric antimicrobial regimen.
3. Assess patients who are candidates for shorter antimicrobial courses.

4. Justify limiting antibacterial treatment when alternate pathogens, such as viruses, are isolated.

Chapter: *Clostridium difficile* and Other GI Infections

Learning Objectives

1. Evaluate the severity of *Clostridioides difficile* infection (CDI).
2. Design medication regimens that will treat current CDI and prevent future episodes.
3. Identify causative pathogens of intra-abdominal infections (IAIs) on the basis of infection type.
4. Design treatment regimens, including drug selection and duration, for common IAIs.

Module III (4.5 CPE): 0217-0000-20-022-H01-P

Chapter: Gastroesophageal Reflux Disease

Learning Objectives

1. Evaluate risk factors associated with developing gastroesophageal reflux disease (GERD).
2. Design a stepwise treatment plan for patients with GERD.
3. Differentiate between proton pump inhibitor nonresponders, and devise a plan for alternative therapy for patients with GERD.
4. Apply pharmacogenomic testing to provide precision medicine to patients with GERD.

Chapter: Peptic Ulcer Disease

Learning Objectives

1. Distinguish peptic ulcer disease (PUD) from other common types of upper GI (UGI) disorders on the basis of symptoms and endoscopic findings.
2. Design an initial drug regimen and plan for monitoring the efficacy of *Helicobacter pylori* treatment.
3. Develop a pharmacotherapy plan for patients who do not respond to initial drug regimens for *H. pylori*.
4. Evaluate the role of acid-suppressive therapy (AST) for patients with NSAID- or aspirin-induced PUD who require continuation of therapy for pain or prevention of cardiovascular events.
5. Assess the role of various AST regimens for UGI bleeding.

Module IV (5.5 CPE): 0217-0000-20-023-H01-P

Interactive Case: Tuberculosis

Learning Objectives

1. Evaluate a patient for risk factors, clinical presentation, and evidence of pathophysiology of tuberculosis (TB) infection.
2. Assess laboratory results, clinical signs, and symptoms to distinguish between active and latent TB.

3. Design an initial drug regimen plan and recommend monitoring values for safety and efficacy for active and latent TB.
4. Design a patient-specific treatment plan for the patient with multidrug-resistant TB.

Interactive Case: Inflammatory Bowel Disease

Learning Objectives

1. Apply results from clinical studies and guidelines to the management of inflammatory bowel disease (IBD) (Crohn disease and ulcerative colitis).
2. Design evidence-based treatment regimens for patients with IBD.
3. According to clinical studies, medication cost, and current guidelines, justify the appropriateness of using biosimilars and other medications in the treatment of IBD.
4. Assess and apply the results from clinical studies focused on therapeutic drug monitoring in providing appropriate treatment recommendations and medication education to patients and health care providers in the treatment of patients with IBD.

Statistics in Practice: Correlation and Regression

Learning Objectives

1. Distinguish regression from correlation models and how each is applied to the analysis and understanding of clinical data.
2. Evaluate the results of common regression and correlation models, and how these results can be used in the interpretation and application of clinical data.
3. Apply the results of a multiple regression model in the analysis of clinical trial data, including how independent variables are best selected for a multiple regression model.
4. Evaluate results from a non-parametric Spearman Rank Order Correlation model.
5. Justify the use of common generalized linear models in regression analysis of different response variable types.